In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis | Zendy

Stefania Zanetti | Zendy; Donatella Usai | Zendy; Alessandro is | Zendy; Guido Fadda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis

Author(s) -

Stefania Zanetti,

Donatella Usai,

Alessandro is,

Guido Fadda

Publication year - 1996

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/37.2.357

Subject(s) - chlamydia trachomatis , rifampicin , erythromycin , rifamycin , microbiology and biotechnology , minimum inhibitory concentration , chlamydia , in vitro , antibiotics , chlamydiaceae , antibacterial agent , biology , chlamydiales , virology , medicine , immunology , genetics

The in-vitro activity of a 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis was compared to that of rifampicin and of erythromycin. The compound showed excellent activity for standard strains as well as isolates from patients with sexually transmitted diseases, being more active than the other drugs tested. SPA-S-565 also showed a low frequency of emergence of resistance. Passage of standard strains at sub-inhibitory concentrations caused an increase in MIC values of rifampicin while those for SPA-S-565 remained unchanged.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research